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Imaging Highlights of the American Heart
Association 2007 Scientiﬁc Sessions
James K. Min, MD, FACC,* Leo Hofstra, MD,† Swaminatha V. Gurudevan, MD,‡
Manuel D. Cerqueira, MD, FACC, FAHA, FASNC§
New York, New York; Maastricht, the Netherlands; Irvine, California; and Cleveland, OhioOf the 3,780 abstracts accepted for presentation at
the American Heart Association (AHA) Scientific
Sessions 2007 in Orlando, 206 belonged to the
cardiovascular imaging category. The following ab-
stracts can be considered the imaging highlights of
2007. From session to session and hall to hall in our
quest to get the best possible abstracts to you, a clear
emphasis was placed this year on computed tomo-
graphic angiography of the coronary arteries and on
multimodality imaging of atherosclerotic plaques.
These techniques place give us hope for a preventive
rather than reactive approach and, if well character-
ized in the ensuing years, they should prove worthy
for better characterization of coronary vessel walls
in individuals at risk.
Seeking COURAGE From the Wizard of Oz. . .
Considerable controversy exists regarding the lack
of added benefit reported for percutaneous coronary
intervention (PCI) plus optimal medical therapy
(OMT) when compared with OMT alone within
the COURAGE (Clinical Outcomes Using Revas-
cularization and Aggressive Drug Evaluation) trial
(1). This randomized controlled trial enrolled 2,287
patients who were followed for 4.6 years, with no
differences identified by treatment strategy for the
primary end point of death or acute myocardial
infarction (1). Although one can argue the limita-
tions of any randomized trial (2), the results of the
From the *Weill Medical College of Cornell University, New York, New
York; †Academic University of Maastricht, Maastricht, the Netherlands;
‡University of California Irvine School of Medicine, Irvine; and the
§Cleveland Clinic Foundation, Cleveland, Ohio. Dr. Min is on the
Speakers’ Bureau of and is a consultant for GE Healthcare.Manuscript received 23 January 2008; accepted January 30, 2008.COURAGE trial suggested to us that, in chronic,
stable angina patients, PCI may be initially safely
deferred. Nearly a decade ago, when planning the
COURAGE trial, the executive committee had
decided to include several substudies that included
evaluation of the role of ischemia with the use of
quantitative myocardial perfusion single-photon
emission computed tomography (SPECT) imaging
(MPI-SPECT) (3). These substudies included
evaluating prognosis in relation to pre-treatment
MPI assessment, utility of MPI to discriminate
optimal treatment strategies for patients with recur-
rent angina, and the role of sequential ischemia
testing by MPI (3). The MPI substudy of the
COURAGE trial was reported at the late breaking
clinical trials and included serial MPI evaluation in
314 of the 2,287 patients (4). Serial MPI in patients
included a pre-treatment and 18-month follow-up
MPI study to examine the impact of intercurrent
treatment on myocardial ischemia. Although there
was no definitive rationale for the timing of the
follow-up scan, numerous key opinion leaders in
the field of cardiovascular medicine agreed by expert
consensus on this follow-up time. The opinion of
the nuclear substudy leadership within COUR-
AGE was that an 18-month window would permit
sufficient time for the effects of medical therapy to
be observed as well as to be beyond the window of
in-stent restenosis. For entry into the MPI COUR-
AGE substudy, patients were required to exhibit
evidence of ischemia upon study entry, as deter-
mined by the local clinical investigator. A total of
25 of the 50 COURAGE sites participated in this
substudy and included sites with large-volume MPI
laboratories that frequently rely on perfusion imag-
ing data to guide therapeutic decision making. The
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253equirement that study entry be limited to those
atients with ischemia was based upon American
ollege of Cardiology (ACC)/AHA guidelines for
argeting anatomic stenosis that may benefit from
CI (5). Furthermore, previous smaller series have
evealed demonstrable reductions in provocative
schemia with medical therapy, as noted in a recent
eview (3). In one report by Schwartz et al. (6),
early one-half of patients with chronic coronary
isease exhibited a sizeable reduction in ischemia
fter 6 months of statin therapy. Thus, at the study’s
nitiation, it was unclear whether reductions in
PI-identified ischemia would be favored in either
f the 2 arms. Shaw et al. (4) presented the results
f this substudy, reporting a marked reduction in
schemia with PCI  OMT when compared with
MT alone. In fact, 33% of the PCI  OMT
atients exhibited a reduction in ischemia that
ncumbered 5% or more of the myocardium based
n quantitative MPI, as compared with only 20%
or those enrolled in the OMT arm (p  0.004)
Fig. 1). This threshold of a change in ischemia
5% of the myocardium was chosen because of its
rognostic significance and the fact that it exceeded
nter-test repeatability (4). Although an inclusion
riterion limited entry of patients to those with
schemia, the COURAGE substudy patients, on
verage, had only mild ischemia (approximately 8%
f the myocardium being ischemic) before treat-
ent. Thus, a greater benefit was anticipated for
hose patients with a greater risk of ischemia (i.e.,
oderate-to-severe ischemia or 10% of the myo-
ardium). In keeping with this expectation, the
esults from this substudy revealed that nearly 80%
f patients with moderate-to-severe severe pretreat-
ent ischemia exhibited a marked ischemia reduc-
ion of5% of the myocardium with PCIOMT
s compared with only 52% of OMT patients (p 
.007) (Fig. 2). Thus, it appears that this latter
hreshold may prove to be an effective entry crite-
ion for future randomized trials. These latter re-
ults are consistent with the tenet in therapeutic
ntervention that greater-risk patients receive a
reater proportional benefit with intervention (7).
o that extent, future work in this area would be
nteresting to examine any added benefit with PCI
ver OMT.
The COURAGE MPI substudy examined the
rimary end point of ischemia reduction and was
nderpowered to examine changes in prognosis.
eaders should, therefore, adopt these results cau-iously and realize the limitations of the report.irst, it reflected a selected subset of only 14% of
he COURAGE-enrolled patients, and myocardial
erfusion single-photon emission computed to-
ography (MPS) was not mandated within
OURAGE, so this sample thereby reflects a
imited understanding of the role of imaging in
herapeutic decision-making. Second, any associa-
ion of prognosis as it relates to MPI-identified
schemia and treatment strategy of angina patients
annot be established by the COURAGE MPI
ubstudy because of a lack of power. These results,
hen, should be viewed as useful primarily for
ypothesis-generating purposes or as helpful for
evising future clinical trials. Definitive statements
bout the benefit of PCIOMT over OMT alone
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254s they relate to long-term outcome cannot be
nferred from this substudy. Third, this substudy
as powered to examine an overall effect of changes
n ischemia and did not consider any key patient
ubsets, including those with previous myocardial
nfarction, with diabetes, who were women, or
hose with impaired left ventricular function. This
atter point is critical for clinicians desiring to
mplement this information into their daily prac-
ice. Finally, the COURAGE MPI substudy results
o not endorse routine 1-year MPS studies. That is,
atients who are angina-free at 1 year do not require
dditional, unnecessary MPS. These results when
sing serial MPI remain outside of standards put
orth in the recent appropriateness criteria (8).
hus, we await additional guidance from updated
ocuments from the ACC to evaluate the role
f serial MPI for patients with chronic coronary
isease.
The COURAGE MPI substudy results are
roundbreaking in that they reflect a decade-long
nquiry by the COURAGE investigators to move
PI beyond the role of risk stratification into a
ealm of fully integrated clinical-decision making.
ecause reductions in ischemia were associated with
mprovements in angina, the COURAGE MPI
ubstudy now establishes the heretofore-unmet
tandard of effectiveness in cardiovascular imaging,
amely, the demonstration of improved health ben-
fits in patients undergoing MPI-guided therapy.
dditional clinical trials are still necessary to elicit
he role of cardiac imaging for guidance of thera-
eutic decision making in other areas of cardiovas-
ular medicine. To date, cardiac imaging trials have
een generally poorly funded, and the lion’s share of
vidence has been derived from prospective, obser-
ational registries. If any single take-home lesson
as learned by the COURAGE substudy, it is that
maging can be an important, if not critical, com-
onent of a clinical trial. Trialists embarking on
uture controlled clinical studies can now consider
he benefit of cardiovascular imaging in the context
f not only future risk stratification, but also of
mproving health outcomes, especially as it relates
o its use as an intermediate outcome.
Along the line of myocardial ischemia assess-
ent, the results of a multicenter Phase III trial
hat used contrast echocardiography with a syn-
hetic biodegradable ultrasound contrast material,
erflubutane polymer microspheres (Imagify, Acu-
phere, Watertown, Massachusetts), were also pre-
ented at the AHA 2007 Scientific Sessions (9). tresented by Roxy Senior, on behalf of investigators
f RAMP (the Real-time Assessment of Myocar-
ial Perfusion Imaging)-1 (n  285) and RAMP-2
n  377 patients) phase III trials, these studies
ook place at 28 international centers in 662 pa-
ients presenting with angina. The primary analyses
ocused on the safety and efficacy of the perflubu-
ane polymer microspheres. These data were com-
ared with quantitative myocardial perfusion stud-
es performed with 99mTc-labeled perfusion tracers
maging at rest and after dipyridamole stress. All
mages were inspected for the presence of wall
otion abnormalities and/or perfusion defects by
ndependent blinded readers, with diagnostic accu-
acy of perflubutane polymer microsphere ischemia
etection determined by quantitative coronary an-
iography in a non-inferiority and superiority anal-
sis. In the RAMP-1 and -2 studies, the prevalence
f significant coronary artery disease was 44% and
8% of patients, respectively. The contrast echocar-
iography results were demonstrated to be either
oninferior or superior to nuclear imaging for
ccuracy, sensitivity, and specificity. Except for a
one case of hypersensitivity in one study patient, no
ide effects of the new contrast agent were observed.
In this issue of JACC: Cardiovascular Imaging, the
esults of OPTIMIZE trial highlighting the role of
ltrasound contrast for stress testing also are pre-
ented. Readers are, however, cautioned that the use
f contrast in the stress setting is not an approved
ndication and is considered off-label. Particular
are should be given to the use of contrast echocar-
iography, given the recent black box warning for
he use of ultrasound contrast agents (10).
Similarly, Carrascosa et al. (11) studied 47 pa-
ients who underwent both stress/rest 99mTc sesta-
ibi SPECT and rest-dipyridamole stress multide-
ector computed tomography (MDCT) cardiac
cans. Overall sensitivity and specificity to detect
tress-induced ischemia as defined by reduction in
yocardial contrast enhancement was 77% and
9%, respectively, compared with SPECT. Reduc-
ions of myocardial contrast enhancement on
DCT scans at rest were associated with high a
ensitivity and specificity of 96% and 98%, respec-
ively, for the detection of myocardial scar.
On the other hand, Shapiro et al. (12) examined
he significance of hypoattenuated left ventricular
yocardium in patients after a first ST-segment
levation myocardial infarction. Using 64-slice cor-
nary computed tomographic angiography
CCTA), 17 patients treated with primary percu-
aneous coronary intervention (average door-to-
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255alloon time 81  34 min) were evaluated with
oth CCTA and cardiac magnetic resonance imag-
ng (CMR; mean 2.9  1.0 days after ST-segment
levation myocardial infarction) and a follow-up
MR at 6 months. Of 680 myocardial segments
valuated, 204 (30%) demonstrated a hypoattenua-
ion pattern that was defined as a perfusion defect.
ransmurality of perfusion defects, as imaged by
CTA, were inversely proportional to left ventric-
lar recovery. Improved regional left ventricular
unction score, when assessed with CMR, was
ssociated with segments with 25% transmurality
42 of 65, 65%) but not 75% transmurality of PD
2 of 23, 9%). On the basis of these preliminary
esults, CCTA holds promise in our ability to assess
yocardial viability and predict left ventricular
ecovery after successful revascularization in pa-
ients presenting with first acute ST-segment ele-
ation myocardial infarction.
In a parallel study of 52 consecutive patients
resenting with first acute myocardial infarction,
oncontrast 64-row CCTA was performed imme-
iately after iodine exposure from selective coronary
ngiography (13). The CCTA scans were com-
ared with electrocardiogram-gated thallium-201
PECT scans within 5 days and 6 months after
nset of myocardial infarction. Hyperattenuated
reas were considered areas of myocardial delayed
nhancement and transmurality and were compared
ith angiographic, SPECT, and clinical data at 6
onths. Three groups were identified: group A
emonstrated transmural delayed enhancement
DE) (n  18) (Fig. 3), group B demonstrated
ubendocardial DE (n  20), and group C demon-
trated no DE (n  14). Group A demonstrated
reater peak creatine kinase, myocardial band (483
286 IU/ml vs. group B, 223  155 IU/ml and
roup C, 129  117 IU/ml, respectively, p 
.0017) with lower incidences of myocardial blush
rade 3 (22% vs, group B 67% and group C 75%, p
0.0071) and left ventricular ejection fraction (41
8% vs. group B 53  13% and group C 62 
1%, p 0.001). Furthermore, during the 6-month
eriod, left ventricular end-diastolic volume in-
reased significantly (110  25 mm3 to 125  21
m3, p  0.042) in Group A, whereas rates of
ehospitalization for heart failure (p  0.0121)
ore often were observed.
ORE-64: Inching Closer to the
ore Expectation!
oronary computed tomographic angiography
ontinues to be evaluated as an exciting new ciagnostic tool for the assessment of obstructive
oronary disease. Although a large number of
ingle-center studies have been reported, the
ORE-64 (Coronary Evaluation Using Multide-
ector Spiral Computed Tomography Angiogra-
hy using 64 Detectors) study, presented at the
HA 2007 Scientific Sessions, represented the
rst prospective, multicenter study to compare
4-slice CCTA to standard quantitative coronary
rteriography (Fig. 4) (14). This study, under-
aken in 9 centers in 7 countries, enrolled 291
atients (40 years of age; calcium scores 600)
ho first underwent CCTA followed by clinically
ndicated conventional coronary angiography,
ith a primary end point of diagnostic ability of
4-slice CCTA to identify patients with signifi-
ant coronary artery disease (CAD). All non-
tented segments 1.5 mm were assessed by 2
ndependent core laboratories with 2 blinded
eaders per laboratory. Coronary artery stenosis
50% by quantitative coronary angiography
QCA) was considered significant, and patients
ere followed clinically for cardiovascular events,
ncluding revascularization. Coronary artery seg-
ents were evaluable in 97% of 291 patients,
nd the prevalence of significant CAD by
CA was 56%. On a per-patient based analysis,
uantitative analysis of stenosis by CCTA re-
ealed an area under the curve of 0.93 (95%
Figure 3. Transmural Hyperenhancement by 64-Slice
Computed Tomography in Group A
Adapted from Sato et al. (12).onfidence interval [CI] 0.90 to 0.96) in
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256omparison with QCA; the overall sensitivity of
uantitative CCTA for detection of a significant
tenosis 50% was 0.85 (95% CI 0.79 to 0.90) and
pecificity 0.90 (95% CI 0.83 to 0.94) (Fig. 5).
iven the disease prevalence rate of 56%, the
ositive and negative predictive values were 0.91
nd 0.83, respectively. Interestingly, on the patient
evel, CCTA demonstrated an equivalent ability to
ts
spected
red for
cath
64-slice
MDCTA
0.5 mm thickness
Cardiac
Catheterization
<30 days
Clinical
Follow-up
30 days
MDCT
Angiography
Calcium score
Conventional
Invasive
Angiography
MDCT Core Lab AngiographicCore Lab
Ca+ >600
Registry
Study Design of the CORE-64 Study
um; CAD  coronary artery disease; MDCT  multidetector com-
ography; MDCTA  multidetector computed tomographic
y.
ROC Area = 0.93
95% CI [0.90-0.96]
1-Specificity
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
vity Specificity PPV NPV
 0.90 0.91 0.83
.90) (0.83-0.94) (0.86-0.95) (0.75-0.89)
ROC Curve and Diagnostic Test Performance and Characteristics
Coronary Computed Tomographic Angiography in the
tudy
dence interval; CORE-64  Coronary Evaluation Using Multidetec-
omputed Tomography Angiography using 64 Detectors; NPV 
redictive value; PPV  positive predictive value; ROC  receiver-6
haracteristics.dentify the need for coronary revascularization,
hen compared with QCA. The diagnostic perfor-
ance of CCTA on “per-patient basis” appeared to
e better as compared to the assessment on “per-
essel basis” (Fig. 6). Given the aforementioned
esults, the study concluded that 64 detector CCTA
an be used to evaluate symptomatic patients for
ignificant CAD as well as the potential need for
evascularization procedures. This late-breaking
tudy, supported by Toshiba Medical Systems and
racco, was presented at the AHA 2007 by Julie
iller, MD, of Johns-Hopkins Medical Center on
ehalf of the CORE-64 investigators. Although
his study confirmed the strong performance of
CTA imaging, particularly a strong positive pre-
ictive value, more evidence is still necessary for
ppropriateness of indications of CCTA in clinical
ractice. However, the CORE-64 study moves the
eld closer to the “core” goal of eventually replacing
tandard invasive coronary angiography by a non-
nvasive test as a diagnostic tool.
In another interesting diagnostic accuracy study,
bdellaoui et al. (15) from the Institut Hospitalier
acques Cartier, France, investigated the role of
CTA in the detection of coronary artery bypass
raft patency. This study evaluated the graft pa-
ency rate in the early post-operative period after
ff-pump bypass grafts and compared the patency
ates with standard on-pump procedures. Of the
34 enrolled patients (median age, 66 years), 11
ere excluded because of arrhythmias or tachycar-
ia in despite beta blockers; in 15 patients, CCTA
ould not be performed because of the inaccessibil-
ty of CCTA at the time of discharge. Of the
emaining 108 patients, CCTA findings were com-
ared in 188 grafts from 69 patients after on-pump
urgery, with 125 grafts in 39 patients after an
ff-pump procedure. The overall graft patency was
8%, including 97% on-pump and 98% off-pump
rocedures.
On the other hand, in a 5-year follow-up of
,971 consecutive primarily low- and intermediate-
isk chest pain patients, all-cause mortality was
xamined in relation to obstructive plaque identified
ith CCTA (Fig. 7) (16). Coronary artery plaque
as assessed by the absence of detectable plaque,
onobstructive plaque, and obstructive plaque.
ompared with adults with no evident coronary
rtery plaque, adults with obstructive coronary
laque were much more likely to die if 1-vessel
bstructive plaque (risk ratio [RR] 5.6, 95% CI 1.56
o 18.9, p  0.01), 2-vessel obstructive plaque (RRPatien
>40 yrs, su
CAD, refer
clinical 
Figure 4.
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257bstructive plaque (RR 26.0, 95% CI 3.6 to 92.1, p
 0.001) was present. Importantly, even the pres-
nce of nonobstructive plaque conferred increased
isk of mortality (RR 2.9, 95% CI 1.6 to 11.5, p 
.01). In keeping with other studies, the 5-year rate
f death for chest pain patients without detectable
oronary artery plaque by CCTA was low (1.8%).
n addition to this long-term follow-up, several
nvestigations were presented that examined the
rognostic value of CCTA to detect other end
oints, including major adverse cardiac events (Ta-
le 1) (17–23).
T Angiography Technology: Faster and Better
he 2007 Scientific Sessions examined 2 recently
ntroduced features to MDCT, namely improved
emporal resolution and increased numbers of de-
ector rows, demonstrating the feasibility of CCTA
se in individuals with higher heart rates and with
ess artifact, respectively.
Burgstahler et al. (24) studied the diagnostic
ccuracy of dual-source CT (DSCT) scanners with
mproved 83-ms temporal resolution in 100 con-
ecutive patients with known or suspected CAD, in
hich image quality using DSCT was evaluated
eighing the impact of heart rate, heart rate vari-
bility and calcification. The average heart rate was
4.0  13.2 beats/min, mean heart rate variability
3.6  36.2 beats/examination, and mean coronary
rtery calcium score 786.5  965.9 Agatston units.
f 90.2% segments that were evaluable, per-patient
nd -segment sensitivity compared with quantita-
ive coronary angiography, specificity, and positive
nd negative predictive values were 100%, 81.5%,
3.6%, and 100% and 91.1%, 92.0%, 75.4%, and
7.5%, respectively. Notably, image quality was
naffected by increasing heart rate but was impacted
y heart rate variability and coronary artery calcifi-
ation. Diagnostic accuracy was unrelated to either
eart rate or variability, but only to coronary artery
alcification.
In a similar study of 65 consecutive patients with
uspected CAD with an average heart rate of 68 
 beats/min, per-patient and per-segment accuracy
ompared with quantitative coronary angiography
or sensitivity, specificity, and positive and negative
redictive values were 100%, 83.3%, 86.9%, and
00% and 98.3%, 96.7%, 86.6%, and 99.9%, respec-
ively (25). Notably, only 2 of 1,160 coronary artery
egments were unevaluable (0.17%). In this cohort,he average coronary artery calcium score was low
100  560 Agatston units), which may explain the
mproved specificity.
Finally, Leber et al. (26) examined 130 patients
ith intermediate likelihood for significant coro-
ary artery disease who were referred for DSCT
nd invasive coronary angiography. Compared with
nvasive coronary angiography, DSCT resulted in a
ensitivity, specificity, and positive predictive value
f 100%, 96%, and 76%, respectively. Notably,
ccuracy to detect a 75% stenosis did not differ in
ROC Area 
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258atients with heart rates 65 beats/min compared
ith 65 beats/min. These three studies demon-
trate the feasibility of DSCT to reliably assess
oronary artery stenosis, albeit at average heart rates
hat are 70 beats/min.
In another major technological development,
56-detector row CT, which permits whole-heart
xial image acquisition in one gantry revolution,
lso was evaluated. With the use of motion-
imulating coronary artery phantoms with varying
eference diameters (1.5, 2, 3, and 4 mm) contain-
ng stenoses of varying severity (0.8 to 3.1mm) and
hape, 256-detector row CT was observed to have
ess artifact than 64-detector row CT by conven-
ional helical image acquisition (27). The reduced
rtifact, however, was not associated with signifi-
ant accuracy difference between diameter and area
easurements between 256-row compared with
4-row scanners.
Further, the ability of 256-row MDCT to quan-
ify subendocardial myocardial blood flow reduction
as evaluated by George et al. (28). In a study of 19
atients with abnormal SPECT perfusion studies,
denosine-induced stress MDCT perfusion imag-
Table 1. Studies Evaluating the Prognostic Value of CCTA
Author (Ref. #) No. of Patients CCTA Predi
Van Werkhoven et al. (17) 426 50% obstructive
abnormal MPI vers
plaque  normal M
Kunimasa et al. (18) 760 Nonobstructive low
plaques by CCTA
Ahmadi et al. (19) 493 Obstructive plaque
Aggarwal et al. (20) 506 No plaque versus
nonobstructive no
plaque
Steinbigler et al. (21) 1,017 Obstructive stenos
Azevedo et al. (22) 218 abnormal or
equivocal stress
test
Obstructive stenos
Aldrovandi et al. (23) 187 No coronary steno
coronary stenosis‘
ACS  acute coronary syndromes; CCTA  coronary computed tomographic an
MPI  myocardial perfusion single-photon emission computed tomography im
angina.ng was performed with 3 serial gantry revolutions it 0.5 s. Using 3-mm short-axis reformations based
pon a 17-segment myocardial model, they trans-
ural perfusion ratio for each sector as the endo-
ardial attenuation density/epicardial attenuation
ensity, with ischemia defined as a total peripheral
esistance0.8 in1 sector. Using50% coronary
tenosis by MDCT within a geographical territory,
eorge et al. (28) reported that the mean total
eripheral resistance was 0.71  0.05 for abnormal
ectors and 1.01  0.06 for normal sectors (p 
.01). Sensitivity and specificity to detect a 50%
tenosis were similar for MDCT and SPECT (62%
nd 86%, respectively, vs. 62% and 71%, respec-
ively, p  NS).
These important studies emphasize the rapid
dvances that are occurring with MDCT technol-
gy, with improvements in temporal resolution and
olume coverage now permitting image acquisition
t higher heart rates and in shorter amounts of time,
espectively. Nevertheless, these studies also high-
ight the current limitations of MDCT, and it is
ikely that reductions in partial volume effects of
alcium or enhanced discriminatory ability to dis-
inguish stenosis within small vessels will require
Clinical End Point Results p Value
ue 
50%
60-day cardiac death,
nonfatal MI, UA, TVR
39% vs. 8% 0.001
nsity MI, UA, cardiac death MI (0.94% vs. 0.05%),
UA (1.13% vs.
0.64%), ACS (2.08%
vs. 0.7%), cardiac
death (0.37% vs.
0.23%)
0.002
CCTA 40-month follow-up
of MI or death
100% event free
survival for patients
with no obstructive
plaque; HR 16.6
(95% CI 4.9 to 55.2)
0.0001
ciﬁed
34-month follow-up
of TVR
0% versus 40% 0.05
602 days for all-cause
death
Exclusion of stenosis
with low risk of
death
8 months cardiac
death, MI, TVR, UA
100% event-free
survival for no
plaque; HR 12.59 for
obstructive stenosis
0.01
ersus 2-year cardiac death,
MI, UA, TVR
100% event-free
survival with no
coronary stenosis
N/A
raphy; CI  conﬁdence interval; HR  hazard ratio; MI  myocardial infarction;
g; N/A  not applicable; TVR  target vessel revascularization; UA  unstablector
plaq
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259redicting Coronary Events:
hinking Outside the Lumen. . .
lthough most of CCTA studies to date have
ddressed the qualitative and quantitative diag-
ostic performance of CCTA for the detection of
oronary stenoses compared with invasive an-
iography, numerous contemporary studies have
egun to evaluate the role of CCTA in charac-
erizing atherosclerotic plaque within the coro-
ary vessel wall. Recent studies evaluating pa-
ients shortly after they have experienced acute
oronary syndromes have demonstrated that the
esions responsible for acute events demonstrate
xpansive remodeling, low Hounsfield unit atten-
ation densities (30 HU) representing necrotic
ores, and spotty calcification. Conversely, stable
laques demonstrate greater density plaques that
re generally not remodeled or negatively remod-
led (29). To evaluate whether CCTA may iden-
ify plaques that may result in acute events
ubsequently, Motoyama et al. from the Fujita
ealth University, Japan, and the University of
alifornia, Irvine, analyzed CCTAs from 1,154
atients who were followed up for at least 12
onths (range 12 to 51 months) (30). The degree
f remodeling as well as the plaque composition
as evaluated for all patients (Fig. 8). Positively
emodeled and noncalcified plaques were charac-
erized for plaque volume and consistency with
oshiba Medical System software, Tustin, Cali-
ornia; lesions with previous PCI and target
esion for elective PCI were excluded. The plaque
haracteristics of lesions resulting in acute coro-
ary syndrome (ACS) were compared with
hose not resulting in ACS (ACS). Ten of
Figure 8. Coronary Computed Tomographic Angiography Revea
Artery (A) Which Was Responsible, As Seen in Conventional Angiog,154 patients experienced ACS, as determined
y CT. Of these, 7 had outwardly remodeled
laques and 6 had necrotic cores; 8 of these
atients had both. The remaining 2 ACS
atients with neither remodeling nor noncalcified
laque lucency demonstrated large calcification.
n ACS patients, these 2 plaque characteristics
ere detected in 54 patients. Total plaque volume
291.9  269.0 mm3 vs. 152.8  78.5 mm3, p 
.002), noncalcified plaque volume (26.0  50.0
m3vs. 3.7  6.4 mm3, p  0.0020), and
aximum noncalcified plaque area in cross-
ectional images (4.7  5.6 mm2 vs. 1.3  1.7
m2, p  0.0004) was significantly larger in
CS group than ACS characteristics group. The
tudy reconfirmed information derived from patho-
ogical studies, namely that lesions responsible for
ubsequent ACS possess larger plaque volume and
hat larger noncalcified plaque area and higher overall
olume.
In another presentation focused on plaque
ssessment, O’Donnell and Voros (31) reported
he role of 18F-fluorodeoxy glucose (FDG)
ositron emission tomographic imaging (PET) in
he assessment of inflammation in coronary vas-
ulature as a marker of plaque vulnerability (Fig.
). They performed CCTA simultaneously with
ET for anatomic delineation of the course of
oronary vessels. O’Donnell and Voros (31) ad-
inistered the Atkins diet and high-fat drinks to
tudy subjects, followed by high-dose beta block-
rs to prevent FDG uptake by the myocardium
nd achieve relatively quiet background. In addi-
ion, they included only patients who underwent
CI either for ACS or stable coronary disease to
llow for easy FDG localization (or absence
Potentially Vulnerable Plaque in the Distal Right Coronaryls a
ram (B), for Acute Coronary Event in Follow-Up
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260hereof) at the site of stent placement. The study
ypothesis was that the patients presenting with
CS have inflamed plaques and, hence, signifi-
ant FDG uptake at the stent site; in contrast,
atients with stable disease do not have inflamed
laques and therefore, should not demonstrate
DG localization in stents. Twenty-five patients
ages 58  10 years, 70% male) were evaluated;
0 patients underwent PCI for ACS, 5 for
hronic stable angina and the remaining 10 pa-
ients with previous stents underwent coronary
ngiography but did not require intervention
32). All patients received 13mCi 18F-FDG fol-
owed by PET (Siemens ECAT HR; Siemens
edical Solutions. Malvern, Pennsylvania) at 3 h
nd 64-slice CCTA (Siemens Sensation; Sie-
ens). Standardized uptake values were obtained
or regions of interest, and target-to-background
atios were calculated. Target-to-background ra-
ios at sites of stent implantation were greater for
he ACS patients (2.3  0.6) compared with
table patients (1.8  0.5; p  0.0004). Also,
DG uptake in the aortic root was greater in the
CS patients (3.6  1.3 vs. 2.5  0.7; p  0.03).
n addition, the glycolytic activity as measured by
DG uptake in the left main coronary vessel was
reater for patients with ACS (2.4  0.6) than
hose who were stable (1.8  0.4; p  0.001)
atients. The result of this study suggest that the
valuation of inflammation in coronary vessels is
ossible with current-generation PET imaging
nd may be used for prognostication as well as to
Figure 9. FDG Uptake in Culprit Lesion Suggestive of Plaque In
18F-ﬂuorodeoxy glucose (FDG) uptake is demonstrated by positron em
depicted by coronary computed tomogrpahic angiography (B). MDCTonitor the efficacy of therapeutic intervention. iagnetic Resonance Imaging of the Vessel Wall:
athering Wisdom From Periphery
imilarly, magnetic resonance imaging (MRI) has
een evaluated for its ability to detect atherosclerotic-
ediated inflammation. Whereas gadolinium
Gd)-enhanced MRI cannot discriminate fibrosis
rom inflammation, small paramagnetic iron oxide
SPIO) may be engulfed by lesional macrophages
nd increase T1-signal intensity. In a study pre-
ented by O’Donnell and Voros (31), 5 patients
nderwent MRI (1.5-T Siemens Aavnto; Siemens)
ith a neck matrix coil before carotid endarterec-
omy. The T1-weighted turbo spin-echo black
lood sequence was used with a repetition time to
ime-to-echo  1,500 ms/10 ms, field of view 179
m, matrix 320  320, and slice thickness 3 mm.
arotid arteries were imaged before and after SPIO
nd gadolinium administration. Both the post-
PIO (7.8 vs. 5.8; p  0.02) and Gd (9.3 vs. 5.8; p
0.02) were greater than the pre-contrast signal.
ron was detected in the inflammation-rich plaques,
nd SPIO particles were found localized to the
acrophages by transmission electron microscopy.
ther MRI studies demonstrated reduction in ath-
rosclerotic plaques with statins, such as the one
resented by Oikawa et al. (32).
The AHA Scientific Sessions 2007 were replete
ith first-of-their-kind investigations examining the
iagnostic performance, clinical utility, and
ypothesis-generating abilities of novel imaging strat-
gies. These studies have begun to establish an excit-
mation
n tomographic imaging (PET) (A) at the site of stent implantation as
ultidetector computed tomography; MI  myocardial infarction.ﬂam
issiong path that future studies can follow. Future work
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261ill help clarify which of the many imaging meth-
ds available at hand will be most beneficial in
hich clinical situations, and we look forward toASNC appropriateness criteria for
single-photon emission computed to- atherosclerosis asseeprint requests and correspondence: Dr. Manuel D. Cer-
ueira, Cleveland Clinic, Nuclear Medicine (Gb3), 9500
uclid Avenue, Cleveland, Ohio 44195. E-mail:hose results. cerquem@ccf.org.1
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